[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-cognitive-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-cognitive-decline":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,72,99,123,154,177,200,222,245,274,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640411","embrace---from-vulnerable-to-empowered-implementation-and-evaluation-of-a-multicomponent-program-to-tackling-age-related-decline-100640411",false,"NCT07628686","EMBRACE - From Vulnerable to Empowered: Implementation and Evaluation of a Multicomponent Program to Tackling Age-related Decline","EMBRACE","Inclusion Criteria:\n\n* MoCA ≥ 17 (Portuguese cutoff point to differentiate between mild cognitive impairment and dementia);\n* Bedside ≥ 20 for literate individuals or 12 for illiterate individuals.\n\nExclusion Criteria:\n\n* Malignant diseases;\n* Diagnosed major depressive disorder;\n* Dementia\u002Fsubstantial cognitive decline (MoCA \\\u003C 17);\n* Symptomatic cardiovascular disease;\n* Revascularization within the last year;\n* Active malignancy;\n* Severe loss of vision, hearing, or communication;\n* Contraindications for physical activity;\n* Neuromuscular diseases;\n* Severe musculoskeletal pathology;\n* Inability to walk independently;\n* Neurological disease affecting language functions;\n* Simultaneous participation in any intervention trial.",true,"ALL","60 Years","80 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","EMBRACE is a randomized, controlled, multi-domain, blinded clinical trial involving 120 community-dwelling older adults at risk of cognitive decline, lasting 12 months. Participants are randomized 1:1 to either a multicomponent intervention group, including cognitive and language training, physical activity, nutritional counseling with oral health support, and financial and digital literacy education, or to a control group receiving regular health counseling. The trial evaluates the effects of the intervention on cognitive performance, quality of life, functionality, financial literacy, digital inclusion, and other health-related outcomes.",[28],"Age-Related Cognitive Decline",[30,31,32,33],"Aging","Cognitive stimulation","Physical activity","Financial and Digital literacy","NOT_YET_RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":22},"2026-06-01",{"date":42,"type":22},"2029-05-31",{"name":44,"class":45},"University Fernando Pessoa","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100547606","cardiac-control-affecting-learning-through-mindfulness-calm-100547606","NCT06410157","Cardiac-Control Affecting Learning Through Mindfulness (CALM)","Inclusion criteria\n\n* Fluent in English\n* Black\u002FAfrican-American or White\u002FEuropean-American\n* Aged between 50-70 years old\n* Non-pregnant and non-menstruating (for at least the past year)\n* Have normal or corrected-to-normal vision and hearing\n* Have reliable access to wifi\n* Have an email account that you check regularly\n* Have a phone that receives text messages\n* Agree to provide blood and urine samples at two campus visits\n* Agree to devote up to 50 minutes daily to this study for 10 weeks as well as attend two campus visits\n\nExclusion criteria\n\n* Have a disorder that would impede performing the breathing intervention (e.g., abnormal cardiac rhythm, arrhythmia, dyspnea)\n* Have cognitive impairment\n* Have regularly played Lumosity games in the past 6 months\n* Have any conditions listed below that are not safe for MRI\n\n  * \\*Metal in any parts of your body\n  * Claustrophobia\n  * Have worked as a machinist, metal worker, or in any profession or hobby grinding metal?\n  * Have had an injury to the eye involving a metallic object (e.g., metallic slivers, shavings, or foreign body)\n  * Cardiac pacemaker\n  * Implanted cardiac defibrillator\n  * Aneurysm clip or brain clip\n  * Carotid artery vascular clamp\n  * Neurostimulator\n  * Insulin or infusion pump\n  * Spinal fusion stimulator\n  * Cochlear, otologic, ear tubes or ear implant\n  * Prosthesis (eye\u002Forbital, penile, etc.)\n  * Implant held in place by a magnet\n  * Heart valve prosthesis\n  * Artificial limb or joint\n  * Other implants in body or head\n  * Electrodes (on body, head or brain)\n  * Intravascular stents, filters\n  * Shunt (spinal or intraventricular)\n  * Vascular access port or catheters\n  * IUD\n  * Transdermal delivery system or other types of foil patches (e.g., Nitro, Nicotine, Birth control, etc.) that cannot be removed for MRI\n  * Shrapnel, buckshot, or bullets\n  * Tattooed eyeliner or eyebrows\n  * Body piercing(s) that cannot be removed for MRI\n  * Metal fragments (eye, head, ear, skin)\n  * Internal pacing wires\n  * Aortic clips\n  * Metal or wire mesh implants\n  * Wire sutures or surgical staples\n  * Harrington rods (spine)\n  * Bone\u002Fjoint pin, screw, nail, wire, plate\n  * Wig or toupee that cannot be removed for MRI\n  * Hair implants that involve staples or metal\n  * Hearing aid(s) that cannot be removed for MRI\n  * Dentures or retainers that cannot be removed for MRI","50 Years","70 Years",{"count":56,"type":22},240,[25],"Some types of meditation lead heart rate to become more steady as breathing quiets whereas others lead to large heart rate swings up and down (oscillations) as breathing becomes deeper and slower. The current study is designed to investigate how daily mindfulness practice with heart rate biofeedback during breathing in a pattern that either increases or decreases heart rate oscillation affect attention and memory and blood biomarkers associated with Alzheimer's disease.",[60,61],"Age-related Cognitive Decline","Alzheimer Disease","RECRUITING","2026-05-11",{"date":65,"type":38},"2026-05-13",{"date":67,"type":38},"2025-01-14",{"date":69,"type":22},"2027-11",{"name":71,"class":45},"University of Southern California",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":19,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100624989","feasibility-and-adherence-to-a-technology-assisted-home-based-strength-training-program-in-adults-with-type-2-diabetes-mellitus-and-mild-cognitive-impairment-100624989","NCT07416799","Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment","Inclusion Criteria:\n\n1. Age: 55-80 years\n2. Diabetes: Diagnosed T2DM with ≥5 years duration\n3. Cognitive Status: Mild cognitive impairment as defined by Petersen criteria and confirmed by Montreal Cognitive Assessment (MoCA) scores of 18-25\n4. Medication Stability: Stable medication regimen for at least 3 months\n5. Physical Capability: Physically capable of participating in moderate-intensity exercise (physician clearance required)\n6. Support System: Having a caregiver or support person willing to assist with technology use if needed\n\nExclusion Criteria:\n\n1. Diagnosis of movement disorders such as multiple sclerosis, parkinson's disease\n2. Diagnosis of Alzheimer's disease,\n3. Current diagnosis of severe depression, major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and\u002For cooperate fully with the protocol.\n4. Significant cerebral vascular disease\n5. Concomitant medications with significant cholinergic or anticholinergic effects or adverse effects on cognition, including antipsychotics, tricyclic antidepressants, anticonvulsants, sedative\u002Fhypnotics, anxiolytics, glucocorticoids (chronic or frequent intermittent),\n6. Visual\u002Fhearing impairment that would significantly impact the ability to participate in psychometric testing.\n7. Significant medical illness or organ failure, including hepatic or renal failure, unstable cardiac disease,\n8. Untreated B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowable).\n9. Uncontrolled hypertension: over 160 mmHg systolic or 100 mmHg diastolic (stable treatment is allowable).\n10. Stage 5 renal impairment (GFR less than 15 or dialysis).\n11. Participation in another clinical trial.\n12. Prisoners.\n13. Exercise Contraindications: Any condition that would make moderate-intensity exercise unsafe such as a history of severe aortic stenosis, poorly controlled hypertension, angina, or syncope.\n14. Lack of Support: No available caregiver or support person for technology assistance","55 Years",{"count":80,"type":22},20,[25],"This is a single-arm feasibility study employing a pre-post design with a 12-week intervention period. The study utilizes a telehealth-assisted home-based resistance exercise program, with a structured progression from supervised to unsupervised sessions over 12 weeks.",[84,85,60],"Type2diabetes","Mild Cognitive Impairment",[87,88,89,90],"Home-Based exercise","Type 2 Diabetes Mellitus (T2DM)","Mild cognitive impairment (MCI)","Ages 55-80","2026-05-07",{"date":63,"type":38},{"date":94,"type":38},"2026-04-14",{"date":96,"type":22},"2027-03",{"name":98,"class":45},"The University of Texas Medical Branch, Galveston",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100375655","the-active-mind-trial-an-adaptive-randomized-trial-to-improve-function-and-delay-dementia-100375655","NCT04171323","The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia","ACTIVE MIND: An Adaptive Clinical Trial of Cognitive Training to Improve Function and Delay Dementia","Inclusion Criteria:\n\n* 55 to 89 years of age\n* Montreal Cognitive Assessment Score of 18-27 inclusive\n* History of some change in cognitive function relative to established baseline and either 1) a CDR of 0.5; or 2) CDR of 0 and a clinical diagnosis of mild cognitive impairment (MCI) based on a multidisciplinary evaluation that included standardized neuropsychological testing\n* If reports use of medications typically prescribed for dementia such as Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, or Reminyl, dose has been stable for at least 30 days\n* Adequate auditory capacity to understand normal speech. No greater than moderate hearing loss evident by thresholds less than or equal to 50 dB at 1000 and 2000 Hz in at least one ear determined by an audioscope.\n* Adequate visual capacity to read from a computer screen at a normal viewing distance as measured by binocular visual acuity of 20\u002F50 or better tested with a standard near visual acuity chart\n* Reports and shows adequate motor capacity to touch a computer screen or control a computer mouse.\n* Wiling to complete all study activities\n* Willing and capable of providing informed consent\n* Ability to understand study procedures and comply with them for the length of the study\n\nExclusion Criteria:\n\n* Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition\n* Dementia diagnosis\n* Clinical Dementia Rating Scale of 1 or greater\n* History of large vessel stroke with significant residual motor or cognitive impairment\n* History of moderate to severe traumatic brain injury with residual cognitive symptoms\n* History of brain tumor\n* Undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening\n* Congestive heart failure diagnosis\n* Primary diagnosis of idiopathic Parkinson's disease\n* Multiple sclerosis or Amyotrophic lateral sclerosis (ALS) diagnosis\n* Evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.\n* Evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (e.g., unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen)\n* Geriatric Depression short scale score \\>5\u002F15. Participants with mood disorders that are treated and stable and have a GDS score \\\u003C 6\u002F15 are not excluded.\n* Any other clinically significant or unstable medical condition (e.g., ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the assessor's opinion would interfere with the ability to carry out study activities.\n* Previous participation in 10 or more hours of a computerized cognitive intervention program in the past two years\n* Previous participation in cognitive intervention research at the study site in the past 2 years\n* Planning on going away or being otherwise unavailable for a period of more than three weeks in the six months following screening\n* Contraindications to MRI such as pacemaker, metal implants in body, or claustrophobia","89 Years",{"count":108,"type":22},1305,[25],"Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to cognitive stimulation (which will serve as a stringent, active control) to modify the functional trajectories of older adults' with MCI, who are at high risk for dementia. The primary objective of the U01 phase was to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). In the R01 phase, the objective is to identify the best combination of CT exercises to delay dementia onset among persons with MCI. The longitudinal endpoint goal is reducing incident dementia. The primary aim of the study is to determine which CT combination has the best probability to delay dementia by producing the largest IADL improvements. The study further aims to explore neuroimaging and novel blood-based biomarkers.",[60,85,112],"Dementia","2025-12-05",{"date":115,"type":38},"2025-12-11",{"date":117,"type":38},"2020-03-03",{"date":119,"type":22},"2028-08-31",{"name":121,"class":45},"University of Alabama at Birmingham",6,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":46},"100545081","multi-organ-responses-to-chronic-physical-activity-and-inactivity-100545081","NCT06377254","Multi-organ Responses to CHronic Physical Activity and INactivity","Concurrent Multi-organ Responses to CHronic Physical Activity and INactivity Intervention, to Increase Research Discovery in Human Health and Wellbeing","CHAIN","Inclusion Criteria:\n\n* Group 1 ('non-sedentary') self-reporting \\\u003C6 sedentary hrs\u002Fday, not actively involved in exercise training or a regular physical activity regimen (\\>8,000 steps\u002Fday).\n* Group 2 ('sedentary') self-reporting ≥8 waking hrs\u002Fday in sedentary activities and\u002For ≤5,000 steps\u002Fday.\n* Aged 50-65y.\n* Overweight (BMI 25-35 kg\u002Fm2).\n* Waist circumference ≥94cm (males) and ≥80cm (females).\n* Willing to alter physical activity levels as instructed for 6 months\n* Without neurological or psychiatric diseases, motor or cognitive restrictions\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Regular medication use that could interfere with measures\n* A history, or evidence, of chronic cardiovascular, metabolic, musculoskeletal, renal or respiratory diseases.\n* Experiencing 'long-COVID', inflammatory bowel disease or malignancy.\n* Uncontrolled hypertension. Stage 1 hypertension (BP ≤160\u002F100mmHg) with no other signs of cardiovascular disease, and blood pressure (BP) managed by routine medication will not be an exclusion.\n* People employed in jobs that would preclude reducing step count and night-shift workers.\n* Females who are pre\u002Fperi-menopausal, (due to effect of oestrogen fluctuations on primary outcomes and the longitudinal study design), but individuals stable on hormone replacement therapy are eligible.\n* Contraindications for MRI.\n* Allergy or sensitivity to local anaesthesia, or dressing adhesive","65 Years",{"count":133,"type":22},40,[25],"Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual.\n\nPersistent physical inactivity is thought to be a key contributing factor to the risk of poor health and functional decline occurring in middle-aged and older adults. It is therefore concerning that most middle-aged adults spend \\>8hrs\u002Fday being sedentary, with average step count of 3000-4000 steps\u002Fday.\n\nTo be able to holistically assess the effectiveness of future strategies to address age-related decline in health, and devise public health messages to help individuals reach older age in better health, it is essential that the complex physiological effects that activity and inactivity have across biological systems are characterised.\n\nThe goal of this intervention study is to compare the impact of physical activity and inactivity on body functioning. Twenty moderately active participants will decrease their physical activity for three months to match the average amount carried out by middle-aged people in the UK. They will then undertake 3-months of reconditioning training to restore their fitness. In addition, twenty sedentary participants will increase their physical activity to UK recommended levels for six months.\n\nBefore and at points during the intervention period, participants will be asked to make some measurements at home and attend the University of Nottingham to have multiple assessments made. These include;\n\n* fitness, muscle strength and function tests,\n* completion of questionnaires and computer-based brain puzzles\n* having muscle and fat tissue biopsies and blood samples taken.\n* The study also involves having MRI scans.\n\nThis 5-year study will commence in January 2024, with participant recruitment starting in March 2024 and finishing in May 2027.",[137,138,60,139],"Sedentary Behavior","Metabolic Syndrome","Age-Related Sarcopenia",[32,141,142,143,144],"middle-age","Physical inactivity","overweight","lifestyle","2025-11-26",{"date":147,"type":38},"2025-12-04",{"date":149,"type":38},"2024-03-12",{"date":151,"type":22},"2028-10-31",{"name":153,"class":45},"University of Nottingham",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":16,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100588955","phase-1-acute-effects-of-thc-in-older-adult-100588955","NCT06948136","Acute Effects of THC in Older Adult","THC-Aging","* Ability to provide informed consent\n* No history (current or past) of unstable or serious medical, neurological or psychiatric conditions.\n* High school education or greater\n* No positive pregnancy test and\u002For lactation\u002F planning to nurse while in this study\n* English speaking","21 Years",{"count":163,"type":22},60,[165],"PHASE1","The primary objective of this study is to determine if increasing age confers greater vulnerability to the acute A) cognitive (e.g., memory, attention, psychomotor function), B) subjective (e.g., anxiogenic and rewarding effects), and C) cardiovascular (heart rate and blood pressure), effects of THC in adults \\> 21 years old. The secondary aims of the study are to explore age-related acute effects of THC on electrophysiological indices of information processing (e.g., auditory steady-state response (ASSR), oddball paradigm \\[P300\\], and resting state cortical noise) and to determine age-related differences in the metabolism of THC.",[60],"2025-08-14",{"date":170,"type":38},"2025-08-18",{"date":172,"type":38},"2025-06-06",{"date":174,"type":22},"2027-11-01",{"name":176,"class":45},"Yale University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100535199","italian-study-with-tailored-multidomain-interventions-to-prevent-functional-and-cognitive-decline-in-community-dwelling-older-adults-100535199","NCT06248723","ItaliaN Study With Tailored Multidomain Interventions to Prevent Functional and Cognitive Decline in Community-dwelling Older Adults","IN TeMPO","Inclusion Criteria:\n\n* Aged 60 or older\n* Mild\u002Fmoderate vulnerability (Primary Care Frailty Index score between 0.07 and 0.21)\n* Cardiovascular risk factors, Ageing and Incidence of Dementia (CAIDE) \\> 6\n* Clinical Dementia Rating (CDR) ≤ 0.5\n* Presence of increased risk of developing dementia by family history (≥ 1 family member with dementia) and\u002For at least one modifiable risk factor, with Lifestyle Index ≥2. Lifestyle index evaluation: each \"Yes\" answer to the following questions = 1 point.\n\n  1. Physical activity less than 2.5 hours per week (defined as physical activity intense enough to lead to sweating and breathlessness)\\*\n  2. Diet: less than 5 servings of fruits and vegetables per day\\*\n  3. Diet: less than 2 servings of fish per week\\*\n  4. Hypertension: diagnosed by a physician or on medication, or Systolic Blood Pressure (SBP)\\>140 mmHg, or Diastolic Blood Pressure (DBP)\\>90 mmHg)\n  5. Diabetes: type 1 or type 2 diagnosed by a physician, or on medication, or HbA1C ≥7 % in the previous 6 months\n  6. Sleep disturbances, depressive symptoms, or mental\u002Fphysical stress symptoms, for at least 1 month, judged by the physician to be disabling in daily life\n  7. BMI ≥ 25 kg\u002Fm\\^2\\*\n  8. Alcohol: \\> 21 alcohol units\u002Fweek\\*. \\*Based on international and WHO guidelines.\n* Informed consent freely given and acquired before the start of the study\n\nExclusion Criteria:\n\n* Diagnosis of dementia or suspected dementia following the screening visit\n* CDR \\> 0.5\n* Residents in residential facilities for the elderly\n* Inability to consent to informed consent and\u002For actively participate in study interventions, according to clinical judgment\n* Any condition that prevents safe involvement in the intervention and\u002For cooperation in the study. For example, a significant neurological or psychiatric condition, including but not limited to brain tumors (benign or malignant), major psychiatric disorders (e.g. current major depressive disorder, schizophrenia, schizoaffective disorder or bipolar disorder), recent brain hemorrhage (parenchymal or subdural), history of concussive head trauma with persistent or significant neurological outcomes, known morpho-structural abnormalities in the brain, active alcohol\u002Fdrug abuse, active uncontrolled disease of any major organ system; history within the last six months of any acute disease of a major organ system requiring emergency care or hospitalization, including revascularization procedures; severe renal or hepatic insufficiency; unstable or poorly controlled diabetes mellitus, hypertension, or heart failure; malignant neoplasms within the past 3 years (except basal cell carcinoma or squamous cell carcinoma in situ of the skin or localized prostate adenocarcinoma in male participants); any clinically relevant abnormality in blood parameters; severe loss of vision, smar or communication ability, such as to prevent cooperation.\n* Enrollment in other trials\n* High performance on screening memory tests: RAVL-T immediate score \\>48 (score ranges 0-75), RAVL-T delayed \\>10 (score ranges 0-15)\n* Planned transfers from the municipality of residence during the duration of the study for a duration longer than 2 weeks.",{"count":185,"type":22},1340,[25],"The goal of this interventional non-pharmacological study is to investigate the effects of a multi-domain intervention ( \"active intervention\"), compared to that followed by normal clinical practice (\"self-guided intervention\"), in older adults. The primary objective is whether these interventions can prevent functional and cognitive decline in at-risk subjects.\n\nThe multi-domain interventions will include physical exercise, a Mediterranean diet-based nutritional plan, cognitive training, regular medical check-ups, oral hygiene treatments and counseling, monitoring and counseling on visual and auditory abilities, counseling on sleep hygiene and treatment, control of cardiovascular, metabolic, and infectious risk factors, adjustment of drug therapy, suggestions for improving social interactions.",[60],[190,112,30],"Cognitive decline","2025-07-24",{"date":193,"type":38},"2025-07-29",{"date":195,"type":38},"2024-07-16",{"date":197,"type":22},"2026-03",{"name":199,"class":45},"University of Milano Bicocca",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":46},"100590206","the-effect-of-reminiscence-therapy-in-elderly-100590206","NCT06964399","The Effect of Reminiscence Therapy in Elderly","Psychological Well-Being and Mindfulness in the Elderly: The Effect of Reminiscence Therapy","Inclusion Criteria:\n\n* Being over 65 years old\n* not having any serious psychiatric disorders\n* not having any diseases such as dementia etc.\n\nExclusion Criteria:\n\n* Having a serious psychiatric disorder\n* Not being able to attend sessions during the research process","100 Years",{"count":209,"type":22},90,[25],"In this study titled \"Psychological Well-Being and Awareness in the Elderly: The Effect of Reminiscence Therapy\", patients will be randomly divided into two groups as experimental and control groups. No intervention will be made to the patients in the control group. Reminiscence therapy will be applied to the patients in the experimental group. Participants will be asked to fill out the scale forms after accepting to participate in the study and obtaining their consent. In addition, after the reminiscence therapy is completed, the experimental and control groups will be asked to fill out the post-test forms.\n\nThe following questions will be answered in the study;\n\n* Does reminiscence therapy affect the psychological well-being levels of the elderly?\n* Does reminiscence therapy affect the awareness levels of the elderly?",[60],"2025-05-07",{"date":215,"type":38},"2025-05-09",{"date":217,"type":38},"2025-04-01",{"date":219,"type":22},"2025-06-30",{"name":221,"class":45},"Muş Alparslan University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":46},"100376657","cognitive-stimulation-for-elderly-bipolar-patients-100376657","NCT04184375","Cognitive Stimulation for Elderly Bipolar Patients","Evaluation of Cognitive Stimulation on Dysexecutive Residual Symptoms in Bipolar Patients Over 65 Years of Age","TONIC","Pre-Inclusion Criteria:\n\n* age \\> 65 years old\n* Diagnosis of bipolar illness for more than 10 years\n* Euthymic phase\n* Understands and speaks French\n* Free, informed and express consent\n\nInclusion Criteria:\n\n* Mild to moderate neuro-cognitive impairments (MMS Test : 16 ≤ score \\\u003C 26)\n\nExclusion Criteria:\n\n* Illiteracy\n* Patient participating in other therapeutic workshops (e. g. psycho-geriatric day hospital care, etc.)\n* Persons deprived of their liberty by a judicial or administrative decision\n* Persons of full age who are subject to a legal protection measure\n* Persons unable to consent\n* Persons who are not members of or beneficiaries of a social security scheme\n* Patient's refusal to participate in the study",{"count":133,"type":22},[25],"Age is a major risk factor for the development of cognitive disorders and neurodegenerative pathologies. Cognitive disorders during the phases of bipolar disease are known to exist, and alterations increase significantly after the age of 65. Drug treatments seem to have only a limited effect. A cognitive stimulation program has proven his benefit to patients over 65 with neurodegenerative diseases (Israel, 2004). We propose to evaluate this cognitive stimulation program that we have adapted to bipolar disease.",[234,235,60],"Bipolar Disorder","Cognitive Impairment","2025-03-13",{"date":238,"type":38},"2025-03-17",{"date":240,"type":38},"2021-03-04",{"date":242,"type":22},"2026-09-03",{"name":244,"class":45},"Groupe Hospitalier de la Rochelle Ré Aunis",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":16,"sex":253,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":46},"100320403","older-breast-cancer-patients-risk-for-cognitive-decline-100320403","NCT03451383","Older Breast Cancer Patients: Risk for Cognitive Decline","Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study","TLC","Inclusion Criteria:\n\nFor cancer patients, eligibility includes:\n\n* being female\n* Age 60+ at diagnosis of a new primary histological confirmed adenocarcinoma breast cancer\n* AJCC stages 0-3 or planning neoadjuvant therapy\n* In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent\n* If currently taking psychoactive medications (including, but not limited to anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at least two months prior to enrollment.\n* Participant report of no previous or current chemotherapy or hormonal treatment use (anastrazole, exemestane, etc.) This does not include hormonal replacement therapy, synthetic thyroid hormones, etc.\n\nFor controls, eligibility includes:\n\n* being female\n* Age 60+\n* In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent\n* If currently taking psychoactive medications (including, but not limited to anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at least two months prior to enrollment.\n\nExclusion:\n\nWe apply the same exclusion criteria for patients and controls.\n\n* Participant report of a history of formal diagnosis of neurological problems (i.e. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, brain tumors, etc.)\n* Participant report of surgery on the brain for any reason (cancerous or non-cancerous tumors, subdural hematomas, AV malformations, increased intracranial pressure, etc.)\n* Participant report of a history of stroke (with the exception of TIA if ≥1 year ago)\n* Participant report of HIV\u002FAIDS\n* Participant report of moderate to severe head trauma (loss of consciousness \\> 60 min or with evidence of structural brain changes on imaging)\n* History of major psychiatric disorder (DSM-IV Axis 1) (i.e. major depressive disorder (untreated or poorly treated), bipolar disorders, schizophrenia, or substance abuse disorders (self-reported and\u002For stated in medical record).\n* Participant report of a history of prior breast or other cancer with the exception of non-melanoma skin cancer. An exception for cases only: women who completed treatment for a previous cancer at least 5 years ago and have not undergone any chemotherapy or hormonal therapy. This previous cancer cannot be breast cancer.\n* Participant report of previous or current chemotherapy or hormonal therapy use\n* Participant use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for Lupus.\n* Visual or hearing impairment that would preclude ability to complete interviews or neuropsychological testing, such as significant macular degeneration or being unable to correct hearing with hearing aides\n* Non-English speaking\n* To participate in the optional neuroimaging portion of the study:\n\nParticipant cannot be claustrophobic Participant cannot have a pacemaker, aneurysm clip or other implants that are not MRI safe Participant cannot have any type of implanted electrical device","FEMALE","105 Years",{"count":256,"type":22},1700,"OBSERVATIONAL","The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.",[260,60,261],"Cancer, Breast","Cognitive Decline",[263,264],"breast cancer","cognitive decline","2025-03-10",{"date":267,"type":38},"2025-03-11",{"date":269,"type":38},"2010-08-01",{"date":271,"type":22},"2025-04-30",{"name":273,"class":45},"Georgetown University",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":298},"100350861","phase-3-preventing-alzheimers-with-cognitive-training-100350861","NCT03848312","Preventing Alzheimer's With Cognitive Training","Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults","PACT","Inclusion Criteria:\n\n* Be age 65 or older at time of consent\n* Have ability to speak and understand English or Spanish\n* Report adequate sensorimotor capacity to perform the computer exercises\n* Report adequate visual capacity to read from a computer screen at a typical viewing distance\n* Show adequate auditory capacity to understand conversational speech\n* Show adequate motor capacity to touch a computer screen or control a computer mouse.\n* Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score \\>=26.\n* Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention)\n* Wiling to complete all study activities\n* Ability to understand study procedures and comply with them for the length of the study\n\nExclusion Criteria:\n\n* Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition\n* Previous participation in a cognitive training study\n* Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions\n* Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation).\n* Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem.\n* Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim\n* Severe depressive symptoms (Geriatric Depression Scale score \\>=5)",{"count":283,"type":22},7600,[285],"PHASE3","Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residential care needs) and indirect (e.g., lost productivity of family caregivers) economic costs. Implementing interventions to prevent MCI and dementia among older adults is of critical importance to health and maintained quality-of-life for millions of Americans. Recent data analyses from the Advanced Cognitive Training in Vital Elderly study (ACTIVE) indicate that a specific cognitive intervention, speed of processing training (SPT), significantly delays the incidence of cognitive impairment across 10 years. The primary contribution of the proposed research will be the determination of whether this cognitive training technique successfully delays the onset of clinically defined MCI or dementia across three years.",[60,288],"Alzheimer's Disease and Related Dementias","2024-09-24",{"date":291,"type":38},"2024-09-26",{"date":293,"type":38},"2019-02-19",{"date":295,"type":22},"2026-01-31",{"name":297,"class":45},"University of South Florida",7,{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":46},"100454226","tas-test-online-motor-cognitive-tests-for-early-detection-of-alzheimers-disease-100454226","NCT05194787","TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease","TAS Test: Determining the Feasibility and Validity of Online Motor-cognitive Testing for Early Detection of Alzheimer's Disease","TASTest","Inclusion Criteria: \\> 50years old\n\nExclusion Criteria: established diagnosis of dementia",{"count":308,"type":22},3000,"Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD \\>10 years before cognitive symptoms begin; and computer vision so people can \"self-test\" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, \\>10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.",[61,112,60],[312,313,314,315],"pre-clinical","early detection","online tests","Artificial intelligence","2023-10-27",{"date":318,"type":38},"2023-10-30",{"date":320,"type":38},"2021-03-05",{"date":322,"type":22},"2030-12",{"name":324,"class":45},"University of Tasmania"]